Ocrelizumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Not to be confused with eculizumab.
Ocrelizumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CD20
Clinical data
Legal status
  • Investigational
Routes Intravenous infusion
Identifiers
CAS number 637334-45-3 N
ATC code None
UNII A10SJL62JY YesY
Chemical data
Formula C6494H9978N1718O2014S46 
Mol. mass 148 kDa
 N (what is this?)  (verify)

Ocrelizumab is a humanized anti-CD20 monoclonal antibody. It targets mature B lymphocytes[1] and hence is an immunosuppressive drug candidate. It is under development by Hoffmann–La Roche's subsidiary Genentech, and Biogen Idec.

It had reached Phase III clinical trials for rheumatoid arthritis[2] and lupus erythematosus,[3] and Phase II for multiple sclerosis (MS)[4] and hematological cancer.[5]

In March 2010, Roche announced the suspension of clinical trials in rheumatoid arthritis and lupus erythematosus. This step followed excess deaths due to opportunistic infections. Development for multiple sclerosis continues.[6]

In October 2010, Roche announced 24-week results from the PhII study in relapse remitting MS. The drug demonstrated a statistically significant reduction in disease activity as measured by brain lesions (measured by MRI scans) and relapse rate compared to placebo. Both doses (200 mg and 600 mg) were well tolerated.

See also[edit]

Other CD20 antagonists :

References[edit]

  1. ^ K. John Morrow Jr (2008-06-15). "Methods for Maximizing Antibody Yields". Genetic Engineering & Biotechnology News (Mary Ann Liebert, Inc.). p. 36. Retrieved 2008-07-06.  (Note: information included in this article only found in table present in print version of article.)
  2. ^ Kausar, F; Mustafa, K; Sweis, G; Sawaqed, R; Alawneh, K; Salloum, R; Badaracco, M; Niewold, TB; Sweiss, NJ (2009). "Ocrelizumab: a step forward in the evolution of B-cell therapy". Expert opinion on biological therapy 9 (7): 889–95. doi:10.1517/14712590903018837. PMID 19463076. 
  3. ^ ClinicalTrials.gov NCT00539838 A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)
  4. ^ ClinicalTrials.gov NCT00676715 A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
  5. ^ Hutas, G (2008). "Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies". Current opinion in investigational drugs (London, England : 2000) 9 (11): 1206–15. PMID 18951300. 
  6. ^ Katie Reid (2010-03-08). Update 2. Roche suspends arthritis treatment after deaths. Reuters. Retrieved 2010-03-08.